Palvella Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Deferred Revenue of -$39.97 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2024-03-29
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$3.60M.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$406.25K.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was $44.87M.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $33.52M, a 474.04% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$39.97M.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$20.18M, a 203.22% decline from fiscal 2021.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2021 was $19.55M.
- Palvella Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2020 was -$14.50M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$39.97M 10-K · filed 2024-03-29 | ||||
| 2022-12-31 | -$20.18M 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | $19.55M 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | -$14.50M 10-K · filed 2022-03-02 | ||||
| 2019-12-31 | -$28.52M 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $9.31M 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$4.01M derived: sum of 2 quarters · filed 2019-03-18 | $40.86M derived: sum of 3 quarters · filed 2019-03-18 | $74.38M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$406.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $44.46M derived: sum of 2 quarters · filed 2017-11-13 | $77.98M 10-Q · filed 2017-11-13 | $77.03M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-06-30 | $44.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $78.39M 10-Q · filed 2017-08-11 | $77.44M derived: sum of 3 quarters · filed 2018-03-15 | $77.03M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-03-31 | $33.52M 10-Q · filed 2017-05-15 | $32.57M derived: sum of 2 quarters · filed 2018-03-15 | $32.16M derived: sum of 3 quarters · filed 2018-03-15 | $31.43M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-12-31 | -$946.80K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$1.36M derived: sum of 2 quarters · filed 2018-03-15 | -$2.09M derived: sum of 3 quarters · filed 2018-03-15 | $3.75M 10-K · filed 2018-03-15 | $3.75M 10-K · filed 2017-03-30 |
| 2016-09-30 | -$412.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$1.14M derived: sum of 2 quarters · filed 2017-11-13 | $4.70M 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | -$727.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $5.11M 10-Q · filed 2017-08-11 | |||
| 2016-03-31 | $5.84M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |